2.09BMarket Cap-9260P/E (TTM)
6.900High5.810Low3.85MVolume6.250Open6.210Pre Close25.47MTurnover2.82%Turnover RatioLossP/E (Static)308.55MShares6.90052wk High-32.82P/B921.89MFloat Cap1.74052wk Low--Dividend TTM136.37MShs Float24.480Historical High--Div YieldTTM17.55%Amplitude1.240Historical Low6.613Avg Price1Lot Size
Amneal Pharmaceuticals Stock Forum
Update
News
Benzinga· 2 mins ago
Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration
Amneal plans to launch two to three branded oncology 505(b)(2) products per year going forward – this is the first of 2024
Update
Wait for institutions to offer guidance before taking out gains !
Do prayers Don’t FOMO
DONT PaNICK
short sellers need to exit their position to cover, HOLD the GAIN(S)
Grrrr! Another one with no details of value to company
Amneal's medicine is an oral formulation of the carbidopa-levodopa combo used to treat Parkinson's disease. IPX203 is currently under review in the US.
Zambon will seek regulatory approval and commercialize IPX203 in Europe, Amneal said.
Financia...
Watching for answer?
The original NDA for IPX203 resulted in a Complete Response Let...
Update
No comment yet